查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014730

止血鉗和組織黏合劑市場：按產品類型、材料類型、應用和最終用戶分類－2026-2032年全球市場預測

Hemostats & Tissue Sealants Market by Product Type, Material Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，止血鉗和組織黏合劑市場價值將達到 76.9 億美元，到 2026 年將成長到 86.3 億美元，到 2032 年將達到 178 億美元，年複合成長率為 12.74%。

主要市場統計數據
基準年 2025 76.9億美元
預計年份：2026年 86.3億美元
預測年份 2032 178億美元
複合年成長率 (%) 12.74%

這是一份清晰權威的止血劑和組織密封膠市場介紹，說明了影響產品採用的臨床、監管和營運因素。

止血和組織密封膠產業已發展成為一個極具影響力的領域，外科創新、手術全期安全和注重成本效益的醫療保健系統管理在此交匯融合。從心血管外科和胃腸外科到一般外科，各專科的臨床團隊都在不斷尋求能夠簡化止血流程、縮短手術時間並減少術後併發症的輔助產品。這些臨床因素，加上技術進步帶來的產品多功能性和易用性（無論是在開放性手術手術還是微創手術中），正在推動市場成長。

外科手術趨勢、材料創新和價值驅動型採購如何重塑產品開發路徑和臨床應用趨勢。

止血劑和組織密封膠領域正經歷著變革性的轉變，這主要得益於外科手術實踐、材料科學和醫療保健系統經濟等趨勢的融合。微創手術和機器人手術的應用範圍不斷擴大，涵蓋了更多複雜的適應症，因此，即使在空間有限以及負壓和灌注等條件下，對能夠可靠發揮作用的製劑的需求也日益成長。為此，製造商正致力於研發新一代的液體和活性止血劑，以增強黏附性和血塊穩定性，同時保持良好的生物相容性。

評估 2025 年美國關稅調整對供應鏈、籌資策略和價格趨勢的多方面影響。

美國於2025年公佈的關稅政策將對止血和組織密封膠生態系統中的相關人員產生多層次的成本和營運影響。依賴全球原料採購或擁有跨境生產基地的製造商可能面臨更高的進口成本，這將對其定價策略和利潤率結構構成壓力。這些壓力可能促使製造商採取近岸外包、與供應商重新談判合約以及審查組件標準化等措施，以降低關稅風險。

深入了解將產品類型、材料分類、臨床應用、最終用戶背景與策略商業化要求連結起來的詳細細分。

精準的市場區隔對於最佳化不同臨床和商業次市場的產品策略和商業化計劃至關重要。依產品類型分類，市場可分為止血劑和組織密封膠。止血劑又可細分為活性止血劑、液體止血劑和機械止血劑，而組織密封膠則分為纖維蛋白膠和合成密封劑。這種產品分類會影響臨床醫生如何根據出血嚴重程度、解剖路徑以及對生物材料與人工材料性能的偏好來選擇輔助藥物。

區域臨床實踐、監管多樣性和生產能力趨勢如何塑造美洲、歐洲、中東和非洲以及亞太地區的差異化策略。

區域趨勢在止血劑和組織密封膠的研究重點、監管路徑和商業策略的發展中發揮著至關重要的作用。在美洲，先進的醫療基礎設施和大量的外科手術催生了對成熟生物止血劑和創新合成密封劑的強勁臨床需求。該地區的相關人員通常優先考慮可靠的臨床證據和與綜合護理模式的整合，這會影響供應商如何展示產品價值以及如何進行報銷談判。

競爭與合作並存的產業趨勢揭示了成熟的製造商、專家和創新者如何塑造其供應、證據和商業化策略。

競爭格局呈現出多元化的特點，既有成熟的外科醫療設備製造商，也有專注於生物製劑的專業公司，還有致力於材料創新和新型給藥形式的敏捷型Start-Ups。憑藉廣泛的分銷網路、整合的銷售團隊以及與醫院建立的長期合作關係，成熟企業在關鍵領域保持著穩固的地位。而新參與企業則傾向於專注於單一適應症的差異化，或致力於開發獨特的聚合物化學技術，以解決尚未解決的操作難題或性能差距。

為領導者提供實用建議，以協調臨床證據、具有韌性的價值鍊和價值主導的業務策略，從而實現永續的招募。

產業領導者應採取多層次策略，協調臨床開發、供應鏈韌性和商業性推廣工作，以確保產品的永續應用。首先，必須投資可靠的臨床證據，將產品性能與重要的圍手術全期結局連結起來。為了支持產品在不同醫療環境中的應用，應將可操作的臨床試驗和真實世界資料收集納入產品上市和上市後規劃。

透明、多方面的調查方法，結合臨床醫師的見解、監管審查和供應鏈分析，為策略建議奠定基礎。

本分析的調查方法結合了定性和定量方法，旨在提供全面而實用的觀點。主要調查包括對循環系統外科、胃腸外科和普通外科的臨床專家以及醫院、門診手術中心和診所的採購經理進行結構化訪談。訪談內容涵蓋了各種止血劑和密封劑的實際應用效果、操作偏好、採購標準以及推廣應用的障礙。

簡明扼要的結論整合了臨床要求、價值鏈韌性以及決定長期實施和價值實現的策略證據的需求。

總之，止血和組織密封膠產業正處於戰略轉折點，臨床需求、材料科學的進步和經濟壓力在此交匯融合。在這種環境下取得成功需要一項整合策略，該策略既要將差異化的產品性能與令人信服的證據相結合，以證明其下游臨床和營運效益。投資於切實可行的臨床項目、穩健的生產和採購模式以及有針對性的商業化策略的相關人員，將更有利於推動產品在各種醫療環境中的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 止血鉗與組織黏合劑市場：依產品類型分類

  • 止血劑
    • 活性止血劑
    • 液體止血劑
    • 機械止血劑
  • 組織密封膠
    • 纖維蛋白膠
    • 合成密封劑

第9章 止血鉗與組織黏合劑市場：依材料類型分類

  • 天然材質
    • 源自牛
    • 人類來源
  • 合成材料
    • 膠原蛋白蛋白
    • 聚合物基

第10章 止血鉗與組織黏合劑市場：依應用領域分類

  • 非手術治療
    • 診斷治療
    • 輕微傷口縫合
  • 外科手術
    • 心血管外科
    • 胃腸外科手術
    • 一般外科

第11章 止血鉗與組織黏合劑市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 醫院

第12章 止血鉗與組織黏合劑市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 止血鉗與組織黏合劑市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 止血鉗和組織黏合劑市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國止血鉗與組織黏合劑市場

第16章：中國止血鉗與組織黏合劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Advanced Medical Solutions Group PLC
  • Aegis Lifesciences Private Limited.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • CooperSurgical, Inc.
  • CryoLife, Inc.
  • CSL Behring
  • CuraMedical BV
  • Grifols, SA
  • Hemostasis, LLC
  • Hologic, Inc.
  • Integra LifeSciences Corporation
  • Johnson & Johnson Services, Inc.
  • KAKEN PHARMACEUTICAL CO., LTD.
  • KATSAN Katgut Sanayi ve Tic. AS
  • Medline Industries, LP.
  • Medtronic PLC
  • Olympus Corporation
  • Owens & Minor
  • Pfizer, Inc.
  • Smith & Nephew PLC
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
  • Vivostat A/S
  • Zimmer Biomet
Product Code: MRR-437E9896A591

The Hemostats & Tissue Sealants Market was valued at USD 7.69 billion in 2025 and is projected to grow to USD 8.63 billion in 2026, with a CAGR of 12.74%, reaching USD 17.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.69 billion
Estimated Year [2026] USD 8.63 billion
Forecast Year [2032] USD 17.80 billion
CAGR (%) 12.74%

A clear and authoritative introduction to the hemostats and tissue sealants environment explaining clinical, regulatory, and operational drivers shaping product adoption

The hemostats and tissue sealants arena has evolved into a high-impact segment at the intersection of surgical innovation, perioperative safety, and cost-aware health system management. Clinical teams are increasingly seeking adjunctive products that streamline hemostasis, reduce procedure times, and mitigate postoperative complications across a diverse array of specialties from cardiovascular and gastrointestinal surgery to general operative workflows. These clinical drivers are complemented by technological advances that expand product versatility and ease of use in both open and minimally invasive settings.

Concurrently, regulatory scrutiny and payer expectations are shaping how manufacturers prioritize evidence generation and value demonstration. That environment encourages multidisciplinary collaboration between R&D teams, clinical champions, and health economics experts to validate real-world outcomes beyond primary efficacy endpoints. As a result, product development now emphasizes not only hemostatic or sealing performance but also handling properties, storage stability, and compatibility with adjunctive devices and implants.

In this context, stakeholders must balance innovation with operational realities. Hospitals and ambulatory providers evaluate products for ease of adoption, staff training requirements, and supply chain reliability, while clinicians weigh the comparative clinical advantages in complex bleeding scenarios. This introductory framing establishes the subsequent discussion of structural shifts, tariff implications, segmentation insights, regional dynamics, competitive behaviors, and practical recommendations for industry leaders navigating the current landscape.

How surgical trends, materials innovation, and value-driven procurement are reshaping product development pathways and clinical adoption dynamics

The field of hemostats and tissue sealants is undergoing transformative shifts driven by converging trends in surgical practice, materials science, and health system economics. Minimally invasive and robotic procedures continue to expand into complex indications, increasing demand for formulations that perform reliably in restricted workspaces and under suction or irrigation conditions. Consequently, manufacturers are investing in next-generation flowable and active hemostat chemistries that enhance adhesion and clot stability while maintaining biocompatibility.

Material innovation is another pivotal axis of change. Advances in polymer engineering and biologics processing have enabled synthetic sealants that mimic fibrinous matrices while offering improved shelf life and standardized performance. These developments are accompanied by refinements in collagen-based scaffolds and composite constructs that target specific tissue interfaces, from vascular anastomoses to visceral serosal surfaces. The net effect is a broader product palette that can be tailored to surgeon preference and procedure-specific hemostatic challenges.

Market dynamics are also shifting as procurement approaches evolve. Health systems increasingly evaluate products within bundled care pathways and value-based contracting frameworks, prompting suppliers to generate evidence on metrics such as reduction in transfusion rates, decreased reoperation for bleeding, and shorter lengths of stay. Parallel to these commercial forces, digital health integration-ranging from inventory management analytics to intraoperative decision support-offers new avenues for differentiating product offerings and demonstrating measurable system-level benefits. Taken together, these transformative shifts are reshaping product roadmaps, clinical adoption trajectories, and competitive positioning across the ecosystem.

Assessing the multifaceted consequences of the 2025 United States tariff adjustments on supply chains, procurement strategies, and pricing dynamics

The tariff environment announced for 2025 in the United States introduces layered cost and operational implications for stakeholders across the hemostats and tissue sealants ecosystem. Manufacturers that rely on global sourcing of raw materials or maintain cross-border production footprints may face increased landed costs, which in turn pressure pricing strategies and margin structures. These pressures can incentivize nearshoring initiatives, contract renegotiations with suppliers, and reexamination of component standardization to mitigate tariff exposure.

Hospitals and ambulatory providers could experience indirect effects through supply chain volatility, with potential impacts on formularies and supplier consolidation strategies. In response, procurement teams may prioritize multi-source qualification, increased safety stock, and longer lead times for critical products. For smaller suppliers and emerging entrants, tariff-related cost increases may magnify barriers to scale, influencing partnership strategies and potentially accelerating mergers or distribution agreements with larger players that can absorb short-term cost fluctuations.

On the regulatory and reimbursement side, the tariff landscape intersects with broader cost-containment efforts, prompting manufacturers to make stronger value propositions based on clinical outcomes and total cost of care. Strategic responses to tariffs may include reformulation to incorporate domestically sourced inputs, reengineering packaging to reduce import duties, or pursuing deeper clinical evidence to support premium pricing where justified by demonstrable improvements in outcomes. Overall, the cumulative impact of the tariff changes will be mediated by each stakeholder's ability to adapt supply chain design, contracting practices, and evidence-based value communication.

Detailed segmentation insights linking product types, material classes, clinical applications, and end-user contexts to strategic commercialization imperatives

A nuanced understanding of segmentation is essential for tailoring product strategy and commercialization plans across distinct clinical and commercial submarkets. By product type, the landscape divides between hemostats and tissue sealants, with hemostats further differentiated into active hemostats, flowable hemostats, and mechanical hemostats and tissue sealants categorized into fibrin sealants and synthetic sealants. This product taxonomy affects how clinicians select adjuncts based on bleeding severity, anatomical access, and preferences for biologic versus engineered material performance.

Material type provides an orthogonal segmentation axis that influences sourcing, regulatory pathways, and perceived clinical risk. Natural materials encompass bovine-derived and human-derived options that carry considerations regarding donor variability, sterilization, and immunogenicity. Synthetic materials include collagen-based and polymer-based constructs that enable batch consistency and tailored degradation profiles but require rigorous biocompatibility validation to gain clinician trust.

Applications span non-surgical and surgical procedures, where non-surgical uses include diagnostic procedures and minor wound sealing and surgical applications encompass cardiovascular, gastrointestinal, and general surgery. The clinical context determines key product requirements such as adhesiveness under dynamic flow conditions, tensile strength at anastomoses, and compatibility with electrosurgical devices. Finally, end-user segmentation across ambulatory surgical centers, clinics, and hospitals informs distribution channel preferences, stocking practices, and purchasing authority, all of which must be considered when designing launch plans and post-market surveillance strategies.

How regional clinical practices, regulatory diversity, and manufacturing capacity dynamics shape differentiated strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics play a critical role in shaping research priorities, regulatory pathways, and commercial strategies for hemostats and tissue sealants. In the Americas, advanced healthcare infrastructure coupled with active surgical volumes creates strong clinical demand for both established biologic hemostats and innovative synthetic sealants. Stakeholders in this region often emphasize robust clinical evidence and integration into bundled care models, which influences how suppliers approach value articulation and reimbursement engagement.

Across Europe, the Middle East & Africa, heterogeneous regulatory regimes and variable procurement practices create a complex operating environment. European markets may favor products with strong comparative effectiveness data and established supply reliability, whereas emerging markets in the broader region prioritize cost-effectiveness and ease of distribution. This diversity necessitates flexible go-to-market strategies that respect local regulatory expectations while leveraging centralized clinical data for cross-border approvals.

The Asia-Pacific region exhibits rapid adoption of minimally invasive techniques and growing investment in domestic manufacturing capabilities. Local innovation ecosystems and evolving regulatory frameworks are increasingly supportive of clinical trials and commercialization of locally developed formulations. Consequently, suppliers that can demonstrate scalable manufacturing, localized regulatory strategies, and partnerships with regional clinical leaders are positioned to capture opportunities presented by rising surgical volumes and capacity expansion in the region.

Competitive and collaborative industry dynamics revealing how incumbent manufacturers, specialists, and innovators are shaping supply, evidence, and commercialization strategies

The competitive landscape is characterized by a mix of established surgical device manufacturers, specialized biologics firms, and nimble startups that emphasize material innovation or novel delivery formats. Legacy players leverage broad distribution networks, integrated sales forces, and longstanding hospital relationships to maintain presence across major specialties, while newer entrants frequently focus on single-indication differentiation or proprietary polymer chemistries that address unmet handling or performance gaps.

Partnerships and licensing agreements are common mechanisms for scaling distribution or integrating complementary technologies, enabling companies to combine clinical credibility with specialized manufacturing expertise. In parallel, contract manufacturing organizations and specialty material suppliers play decisive roles in ensuring quality, regulatory compliance, and capacity scalability, particularly for products with biologic inputs or complex polymer synthesis requirements.

Strategic priorities among firms include expanding indications through targeted clinical studies, optimizing product portfolios for minimally invasive platforms, and demonstrating health economic value that resonates with hospital procurement committees. Companies that align R&D investment with clear clinical endpoints and that can articulate system-level economic benefits will more effectively influence formulary decisions and surgical practice patterns.

Actionable recommendations for leaders to align clinical evidence, resilient supply chains, and value-driven commercial strategies for sustainable adoption

Industry leaders should adopt a multi-layered approach that aligns clinical development, supply chain resilience, and commercial engagement to secure durable adoption. First, investment in robust clinical evidence that links product performance to meaningful perioperative outcomes will be essential; pragmatic trials and real-world data collection should be integrated into launch and post-market plans to support adoption across diverse care settings.

Second, companies should reexamine supply chain architectures to mitigate tariff exposure and logistical disruptions. Strategies may include qualifying alternative raw material sources, pursuing localized manufacturing partnerships in key regions, and redesigning packaging to reduce cross-border duties. These measures should be complemented by transparent communication with procurement teams to build trust during periods of pricing and availability adjustments.

Third, commercialization should emphasize clinician training, clear handling guidance, and demonstration of compatibility with minimally invasive workflows and adjunctive devices. Tailored value propositions for ambulatory surgical centers, clinics, and hospitals will help address distinct purchasing behaviors and clinical workflows. Finally, proactive engagement with payers and health system value officers to present comprehensive outcome and cost narratives will support positioning in value-based care discussions and bundled payment arrangements.

A transparent, multi-method research methodology combining clinician insights, regulatory review, and supply chain analysis to inform strategic recommendations

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure a comprehensive and actionable perspective. Primary research involved structured interviews with clinical specialists across cardiovascular, gastrointestinal, and general surgery, as well as procurement leaders from hospitals, ambulatory surgical centers, and clinic settings. These discussions focused on real-world clinical performance, handling preferences, purchasing criteria, and adoption barriers for different hemostat and sealant categories.

Secondary analysis incorporated peer-reviewed clinical literature, regulatory guidance documents, product labeling, and manufacturing standards to validate material performance claims and regulatory pathways. Supply chain mapping and tariff impact assessment were conducted using trade flow analyses, input cost reviews, and consultation with industry procurement experts to identify likely operational implications and mitigation strategies.

Triangulation across data sources was used to corroborate findings and surface strategic implications. The methodological framework prioritized transparency in source attribution, reproducibility of analytic steps, and sensitivity to regional regulatory variance. Limitations and data gaps were identified to guide future research priorities and targeted primary data collection where necessary.

A concise conclusion synthesizing clinical imperatives, supply chain resilience, and strategic evidence needs that determine long-term adoption and value realization

In conclusion, the hemostats and tissue sealants sector stands at a strategic inflection point where clinical needs, material science advances, and economic pressures converge. Success in this environment requires an integrated strategy that pairs differentiated product performance with compelling evidence of downstream clinical and operational benefits. Stakeholders who invest in pragmatic clinical programs, resilient manufacturing and sourcing models, and targeted commercialization approaches will be best placed to influence adoption across heterogeneous care settings.

Tariff-driven cost dynamics and evolving procurement behaviors underscore the importance of agility in supply chain design and clarity in value communication. Meanwhile, regional opportunities vary in their regulatory expectations and infrastructure maturity, so localization of regulatory and commercialization approaches will remain a competitive advantage. Ultimately, the companies that can harmonize innovation with demonstrable hospital and patient-level outcomes will shape standards of care and capture the most sustainable opportunities in this evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemostats & Tissue Sealants Market, by Product Type

  • 8.1. Hemostats
    • 8.1.1. Active Hemostats
    • 8.1.2. Flowable Hemostats
    • 8.1.3. Mechanical Hemostats
  • 8.2. Tissue Sealants
    • 8.2.1. Fibrin Sealants
    • 8.2.2. Synthetic Sealants

9. Hemostats & Tissue Sealants Market, by Material Type

  • 9.1. Natural Materials
    • 9.1.1. Bovine-Derived
    • 9.1.2. Human-Derived
  • 9.2. Synthetic Materials
    • 9.2.1. Collagen-Based
    • 9.2.2. Polymer-Based

10. Hemostats & Tissue Sealants Market, by Application

  • 10.1. Non-Surgical Procedures
    • 10.1.1. Diagnostic Procedures
    • 10.1.2. Minor Wound Sealing
  • 10.2. Surgical Procedures
    • 10.2.1. Cardiovascular Surgery
    • 10.2.2. Gastrointestinal Surgery
    • 10.2.3. General Surgery

11. Hemostats & Tissue Sealants Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Hemostats & Tissue Sealants Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hemostats & Tissue Sealants Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hemostats & Tissue Sealants Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hemostats & Tissue Sealants Market

16. China Hemostats & Tissue Sealants Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Advanced Medical Solutions Group PLC
  • 17.7. Aegis Lifesciences Private Limited.
  • 17.8. B. Braun SE
  • 17.9. Baxter International Inc.
  • 17.10. Becton, Dickinson and Company
  • 17.11. Cardinal Health, Inc.
  • 17.12. CooperSurgical, Inc.
  • 17.13. CryoLife, Inc.
  • 17.14. CSL Behring
  • 17.15. CuraMedical B.V.
  • 17.16. Grifols, S.A.
  • 17.17. Hemostasis, LLC
  • 17.18. Hologic, Inc.
  • 17.19. Integra LifeSciences Corporation
  • 17.20. Johnson & Johnson Services, Inc.
  • 17.21. KAKEN PHARMACEUTICAL CO., LTD.
  • 17.22. KATSAN Katgut Sanayi ve Tic. A.S.
  • 17.23. Medline Industries, LP.
  • 17.24. Medtronic PLC
  • 17.25. Olympus Corporation
  • 17.26. Owens & Minor
  • 17.27. Pfizer, Inc.
  • 17.28. Smith & Nephew PLC
  • 17.29. Stryker Corporation
  • 17.30. Teleflex Incorporated
  • 17.31. Terumo Corporation
  • 17.32. Thermo Fisher Scientific Inc.
  • 17.33. Vivostat A/S
  • 17.34. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY ACTIVE HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FLOWABLE HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MECHANICAL HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY BOVINE-DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HUMAN-DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY POLYMER-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MINOR WOUND SEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GASTROINTESTINAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 191. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 192. GCC HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 224. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 225. G7 HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 235. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 236. NATO HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY HEMOSTATS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY TISSUE SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NATURAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SYNTHETIC MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY NON-SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA HEMOSTATS & TISSUE SEALANTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)